ARQ 531 is primarily investigated for its potential in treating various cancers, particularly those involving B-cell malignancies and solid tumors. It functions as a reversible inhibitor of Bruton's tyrosine kinase (BTK), which plays a critical role in B-cell receptor signaling. By targeting BTK, ARQ 531 disrupts the survival and proliferation of cancerous B-cells. Additionally, it has shown efficacy in overcoming resistance to other BTK inhibitors, making it a promising candidate for patients who have developed resistance to first-generation therapies like ibrutinib. Its broad-spectrum activity also extends to other kinases, potentially expanding its therapeutic applications. Ongoing clinical trials aim to evaluate its safety, tolerability, and effectiveness in treating relapsed or refractory hematologic cancers.